Global Fungal Infections Market – Industry Trends and Forecast to 2029

Global Fungal Infections Market, By Types (Aspergillosis, Blastomycosis, Candidiasis, Candida auris, Coccidioidomycosis, Cryptococcus gattii Infection, Fungal Eyes Infection, Fungal Nail Infection, Histoplasmosis, Ringworm, Others), Drugs (Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Others), Treatment (Antifungal, Others), Route of Administration (Oral, Parenteral, Topical, Vaginal, Others), Dosage Form (Creams, Gels, Ointment, Solution, Lotions, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.

Fungal Infections Market Analysis and Size

The global fungal infections market is expected to witness significant growth during the forecast period. The symptoms of fungal infections depend on the type of fungal infection. The common symptoms include itching and skin changes, including red and possibly peeling or cracking skin. This type of infection can be treated with antifungal medications. These medications can kill fungi directly or prevent them from thriving and growing. Antifungal drugs are available in several formulations, including powder, pills, sprays, shampoos, and creams or ointments.

Data Bridge Market Research analyses a growth rate in the global fungal infections market in the forecast period 2022-2029. The expected CAGR of the global candida infections drugs market tends to be around 4.00% in the mentioned forecast period. The market was valued at USD 14.42 billion in 2021, and it would grow up to USD 19.73 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Fungal Infections Market Scope and Segmentation

Market Definition

Fungal infections are common in the natural world. Infection occurs when an invading fungus enters the body, and the immune system becomes too weak to handle the abnormalities. Fungal infections can occur anywhere on the body. The most common fungal infections are ringworm, jock itch, athlete's foot, and yeast. This disease prevalence is rising, and important diagnostic procedures and treatments will boost the market's growth.

Global Fungal Infections Market Dynamics

Drivers

• Increased Demand for Diagnostic Tests

Diagnostic tests, such as medical imaging, including C.T. scans and X-rays, are usually performed to detect pneumocystis pneumonia. In addition, biopsy involves extracting a small part of the infected tissue and is examined under the microscope for the presence of a specific fungus. It is generally performed for the diagnosis of aspergillosis, pneumocytosis pneumonia, and sporotrichosis. Thus, it acts as a major driver in market growth.

• The rise in Cryptococcal Meningitis

As per the Centers for Disease Control and Prevention, an estimated 220,000 new cases of cryptococcal meningitis occur globally every year, and around 181,000 deaths occur because of cryptococcal meningitis. Cryptococcal meningitis is a deadly brain infection caused by the soil-dwelling fungus Cryptococcus.

Opportunities

• Rising Existence of Several Fungal Infections

Several fungal infections are helping in boosting the growth of the market. Pneumocystis pneumonia is the most severe and commonly occurring fungal infection that is caused by the fungus Pneumocystis jirovecii. It is most widespread in individuals with weakened immune systems, such as those with AIDS. Other than these, Dermatophytes and Candidiasis are two other types of commonly occurring fungal infections. Candidiasis majorly affects soft, moist areas or skin around the nails. For instance, vaginal yeast infection in women and baby diaper rash occurs because of candidiasis. All these factors are also contributing to the growth of the market.  

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs used for the global fungal infections market delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel unable to perform these treatments could reduce the growth of the global fungal infections market over a forecast period.

• Unavailability of Appropriate Treatments

To treat conditions that are rare, many times, all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.

This global fungal infections market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global fungal infections market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Fungal Infections Market

Even though in the COVID-19 pandemic, the shift was on eliminating the infection and vaccine production, the fungal infections were hit, and the link between the two was established. Currently, fungal infection cases are increasing among people because of the ideal environment in COVID-19 patients, low oxygen, acidic medium (diabetic ketoacidosis and others), high iron levels, high glucose, and suppressed immune system, along with other comorbidities. Government authorities are spreading more and more awareness for the early detection and management of fungal infections in COVID-19 patients. For instance, guidelines have been released by the Indian Council of Medical Research (ICMR), i.e., Do's and Don'ts for the COVID – 19 patients.

Global Fungal Infections Market Scope

The global fungal infections market is segmented on the basis of types, drugs, treatment, dosage form, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Aspergillosis
• Blastomycosis
• Candidiasis
• Candida auris
• Coccidioidomycosis
• Cryptococcus gattii infection
• Fungal Eyes Infection
• Fungal Nail Infection
• Histoplasmosis
• Ringworm
• Others 

Drugs

• Corticosteroids
• Corticosteroid-Sparing Agents
• Immunosuppressive
• Immunomodulator
• Antifungals
• Others

Treatment

• Antifungal
• Others

Dosage Form

• Creams
•  Gels
•  Ointment
• Solution
• Lotions
• Others

Route of Administration

• Oral
• Parenteral
• Topical
• Vaginal
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Fungal Infections Market Regional Analysis/Insights

The global fungal infections market is analysed and market size insights and trends are provided by drugs, treatment, dosage form, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the global fungal infections market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to the highest number of patients diagnosed with a skin infections and increased R&D and healthcare expenditure.

Asia-Pacific is considered to have the most lucrative period due to increased campaign programs for skincare products, favorable environmental conditions for manufacturing, and number of generic drugs. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Fungal Infections Market Share Analysis

The global fungal infections market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global fungal infections market.

Key players operating in the global fungal infections market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)